{"id":"W4399369977","doi":"10.1016/s0140-6736(24)00701-3","title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Genentech; Astellas Pharma; Eisai; Servier; Moderna; Yuhan; LG Chem; Advanced Accelerator Applications; Sanofi; Halozyme; Exelixis; Ipsen; BeiGene; Mirati Therapeutics; Handok; Amgen; Pfizer; Recordati Rare Diseases; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Octreotide; Medicine; Neuroendocrine tumour; Neuroendocrine tumors; DOTA; Urology; Internal medicine; Nuclear medicine; Somatostatin; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001552233,0.001819768,0.002865514,0.0003407706,0.0003329529,0.001206802,0.001135527,0.002014563,0.004213223],"category_scores_gemma":[0.00135182,0.0009134802,0.002096056,0.0004341611,0.001539733,0.001366138,0.0003553299,0.003790676,0.0009083659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001182294,"about_ca_system_score_gemma":0.001078146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001971785,"about_ca_topic_score_gemma":0.003531304,"domain_scores_codex":[0.9994391,0.0002929496,0.00003073271,0.00009238741,0.00004104365,0.0001038172],"domain_scores_gemma":[0.9992973,0.0002696173,0.0001212858,0.00005588724,0.0000291544,0.0002267906],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9822078,0.003636693,0.0002160203,0.0003501627,0.0006016332,0.00003070775,0.00004303364,0.0003720892,0.00307144,0.00008010401,0.0003675841,0.009022644],"study_design_scores_gemma":[0.9042715,0.0928155,0.0009023257,0.00002264811,0.0004463262,0.00003655172,0.00002277847,0.0004441043,0.0004601631,0.0001173446,0.0004408256,0.00001988574],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902297,0.004438404,0.0006750521,0.0005323272,0.0006872296,0.001362907,0.000557988,0.0001033571,0.001413014],"genre_scores_gemma":[0.9876204,0.003097193,0.001729052,0.0008999415,0.0003987062,0.001723606,0.0007800948,0.00004580464,0.003705109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004213223,"threshold_uncertainty_score":0.01409459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08115582454593431,"score_gpt":0.3982719218759983,"score_spread":0.317116097330064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}